# Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

> **NCT00306553** · PHASE2 · COMPLETED · sponsor: **Cytos Biotechnology AG**

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** CYT004-MelQbG10

## Key facts

- **NCT ID:** NCT00306553
- **Lead sponsor:** Cytos Biotechnology AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2006-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00306553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00306553, "Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00306553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*